The article is a good find so perhaps the writer of the press release just made a simple mistake in researching diabetic testing companies. Certainly, nothing nefarious to see. The patch has always been an effective and quality delivery system. If the writer is correct I am quite surprised that first yeard sales were that strong.

Puzzling why the person that found the article was accused of altering the press release. It goes without saying any investor wants higher share prices, which generally is symbiotic with progress and success of the underlying security.